BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-compounding-peptide-adcom-july-2026@catalyst-calendar.local
DTSTAMP:20260720T200527Z
DTSTART:20260723T120000Z
DTEND:20260723T123000Z
SUMMARY:FDA药房复方咨询委员会503A多肽原料评议会议
DESCRIPTION:FDA Pharmacy Compounding Advisory Committee将于7月23日至24日讨论多种多肽是否纳入503A bulk drug substances list。该窗口可能影响复方药房、肽类产品监管边界及部分GLP-1/代谢药物外溢监管预期。\\nImpact score: 66\\nExpected: 关注委员会对BPC-157、KPV、TB-500、MOTS-c、Semax等多肽复方使用边界的建议，以及FDA后续对复方药品监管态度。\\nAffected: XBI(etf\, unknown\, score 60)\; LLY(peer\, unknown\, score 58)\; NVO(peer\, unknown\, score 58)\; IBB(etf\, unknown\, score 56)\; CVS(customer\, unknown\, score 50)\\nSources: FDA PCAC meeting announcement: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026\\nFederal Register notice: https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request\\nFDA advisory committee calendar: https://www.fda.gov/advisory-committees/advisory-committee-calendar\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-compounding-peptide-adcom-july-2026
CATEGORIES:fda\,US\,FDA\,compounding\,peptides\,503A\,PCAC
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA药房复方咨询委员会503A多肽原料评议会议
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA药房复方咨询委员会503A多肽原料评议会议
END:VALARM
END:VEVENT
END:VCALENDAR